AZD1390: ATM Kinase Inhibitor Workflows

AZD1390 is a selective ATM kinase inhibitor designed for experiments that interrogate DNA damage response signaling, checkpoint control, and radiation sensitivity. Its most useful applied role is not simply reducing ATM activity; it is separating ATM-dependent survival responses from downstream effects caused by ionizing radiation, replication barriers, or defective DNA repair.

The compound is especially relevant as a radiosensitizer for glioma and lung cancer. The AZD1390 product information reports a cellular IC50 of 0.78 nM, inhibition of ATM in LN18 glioblastoma cells at 3 nM, and enhanced radiation responses in NCI-H2228 cells at 10 nM. These values should be treated as literature- and model-specific starting points rather than universal working concentrations.

Setup and principle: isolate ATM-dependent radiation responses

ATM is activated by DNA double-strand breaks and coordinates repair, checkpoint enforcement, and cell-fate decisions. Blocking this kinase can prevent cells from mounting an effective response to radiation-induced lesions, creating a controlled way to test whether a phenotype depends on ATM signaling. In practical terms, AZD1390 can be used as a DNA double-strand break repair inhibitor in combination studies, provided that solvent, radiation-only, and compound-only controls are included.

A useful design begins with a four-arm comparison: vehicle control, AZD1390 alone, radiation alone, and AZD1390 plus radiation. The primary readout may be short-term pathway inhibition, while secondary readouts can include clonogenic survival, cell-cycle distribution, micronuclei, apoptosis, or residual DNA damage. The product dossier describes G2 arrest, micronuclei formation, and apoptosis in irradiated NCI-H2228 cells, while enhanced effects have also been observed in p53-mutant glioma models according to the product information.

For reproducible sourcing, APExBIO supplies AZD1390 as a solid compound with reported purity of at least 98%. Because the compound is insoluble in water, prepare a concentrated organic stock and introduce it into culture medium gradually. The product information reports solubility of at least 19.6 mg/mL in DMSO and at least 3.04 mg/mL in ethanol with gentle warming and ultrasonic treatment; long-term storage of prepared solutions is not recommended in the product information.

Step-by-step workflow for radiation and DNA damage studies

1. Establish the cellular response window

Begin with a concentration-response experiment in each cell line before adding radiation. Use a broad low-nanomolar range and measure viability, pathway markers, and cell-cycle distribution. The goal is to identify a concentration that suppresses ATM-dependent signaling without producing excessive compound-only toxicity. Include untreated and solvent-matched wells, because a strong DMSO gradient can confound both viability and stress responses.

2. Add AZD1390 before the DNA-damaging challenge

Preincubation allows ATM inhibition to be present when radiation-induced lesions arise. Collect an early sample for pathway analysis and a later sample for cell-cycle or apoptosis measurements. A practical sequence is to expose cells to AZD1390 before irradiation, maintain the compound during the post-radiation period, and then compare the time course with radiation alone. This design distinguishes failure to initiate signaling from delayed loss of viability.

3. Pair orthogonal endpoints

Do not rely on one viability assay to define radiosensitization. Combine a short-term metabolic or ATP-based assay with at least one structural or functional endpoint. Flow cytometry can resolve G1, S, and G2/M populations; microscopy can score micronuclei; and long-term colony formation can reveal whether apparently surviving cells retain proliferative capacity. Immunoblotting or imaging of ATM-pathway markers provides a mechanistic bridge between compound exposure and phenotype.

4. Use interaction analysis rather than visual comparison

Construct a two-dimensional matrix of AZD1390 concentration and radiation dose when the objective is to quantify combination effects. Analyze the matrix with a prespecified additivity or synergy model and report biological replicates separately. A compound that lowers viability on its own can appear to radiosensitize simply because the two stressors are being compared at unequal baselines. Normalize carefully and retain raw values for each condition.

Protocol Parameters

• Stock preparation: dissolve AZD1390 in DMSO at 10 mM, using gentle warming at 25–37 °C and brief ultrasonic treatment; prepare 20–50 µL aliquots and store them at −20 °C.
• Cell exposure: seed 2,000–5,000 cells per well in a 96-well plate, allow 16–24 hours for attachment, and pretreat with 0.3–30 nM AZD1390 for 1–2 hours before radiation.
• Radiation comparison: test a 2–8 Gy radiation range, keep the inhibitor present for 6–24 hours after exposure, and collect early signaling samples at 0.5–2 hours.
• Replication design: use at least 3 biological replicates per condition, keep final DMSO at or below 0.1% v/v, and measure viability or apoptosis 48–96 hours after treatment.

These are workflow starting conditions for optimization, not universal specifications. The 3 nM LN18 and 10 nM NCI-H2228 values described in the product dossier can help anchor pilot experiments, but cell density, radiation dose, ATM abundance, p53 status, and assay duration may shift the effective window.

Key Innovation from the Reference Study

The reference study, Human REV1 interacts with DHX36 to promote replication and tolerance of G-quadruplex DNA, identifies a direct functional relationship between the REV1 C-terminal domain and the G-quadruplex helicase DHX36. The work shows that REV1 helps coordinate G-quadruplex resolution, replication fidelity, and suppression of single-stranded DNA gaps. Loss of REV1 redirected fork elongation toward a PrimPol-driven mechanism, increased nuclear G-quadruplex signal, amplified ATM/ATR signaling, and sensitized cells to G-quadruplex-stabilizing conditions.

This finding changes how an ATM-inhibitor experiment can be framed. Instead of treating replication stress as an undifferentiated background, investigators can ask whether a G-quadruplex-processing defect creates an ATM-dependent vulnerability. A practical assay set would compare control and REV1-deficient cells, measure nuclear G-quadruplex signal and replication-associated gaps, and then add AZD1390 with or without radiation. DNA-fiber analysis, cell-cycle profiling, micronucleus scoring, and apoptosis measurements can reveal whether ATM inhibition converts a tolerable fork barrier into irreversible damage.

Importantly, the reference study did not establish that AZD1390 directly disrupts the REV1–DHX36 interaction. Therefore, any connection between this ATM kinase inhibitor and G-quadruplex tolerance should be presented as a testable mechanistic hypothesis. The strongest design uses genetic or pathway controls, a matched solvent control, and independent measurements of ATM signaling rather than inferring pathway engagement from reduced viability alone.

Advanced applications and comparative advantages

AZD1390 is valuable in cancer research because it supports several linked but distinguishable use cases:

• Glioblastoma radiosensitization: test whether ATM blockade increases radiation-induced checkpoint failure and loss of clonogenic recovery, with particular attention to p53-mutant backgrounds.
• Lung cancer response profiling: examine the relationship among radiation, G2 arrest, micronuclei, and apoptosis in NCI-H2228 or related models.
• Replication-stress studies: combine ATM inhibition with genetic perturbation of replication-tolerance factors to determine whether damage accumulates at difficult-to-replicate DNA structures.
• Translational dose selection: use cellular response curves to prioritize exposure ranges before moving to animal studies. The product dossier reports dose-dependent tumor-growth inhibition in an orthotopic rat lung-brain tumor model, with stronger efficacy at 20 mg/kg combined with ionizing radiation according to the product information.

The radiosensitization workflow guide complements this article by emphasizing radiation-response setup and troubleshooting. The ATM kinase inhibitor workflow extends the same concept toward checkpoint and replication-stress assays, while the replication-stress assay design resource provides a useful bridge to G-quadruplex-associated biology. Together, they complement rather than replace direct pathway validation.

Why this cross-domain matters, maturity, and limitations

Connecting ATM inhibition with REV1–DHX36-dependent G-quadruplex tolerance is scientifically useful because the reference study links defective G-quadruplex processing to stronger ATM/ATR signaling and treatment sensitivity. However, this bridge currently supports assay development more strongly than it supports a completed therapeutic mechanism. The study does not test AZD1390, radiation combinations, or the product in REV1-deficient cells. Consequently, researchers should use the connection to generate matched experiments, not to claim that ATM inhibition is already proven to target the REV1–DHX36 axis.

Troubleshooting and optimization tips

Unexpected precipitation or variable potency

Confirm that the stock is fully clear before dilution and that the final DMSO concentration is identical across wells. Add the stock slowly into vigorously mixed medium rather than placing a concentrated droplet directly on cells. Avoid repeated freeze-thaw cycles and prepare fresh working dilutions because prolonged solution storage can change the effective exposure.

High compound-only toxicity

Reduce concentration, shorten pretreatment, or lower cell density only after checking whether the solvent is responsible. A useful control is a DMSO titration without AZD1390. If toxicity remains, compare early ATM pathway inhibition with later viability loss; the most informative radiosensitization window may occur below the concentration that causes substantial compound-only killing.

No apparent radiation enhancement

Verify radiation calibration, cell-cycle distribution, compound timing, and ATM pathway engagement. A radiation dose that is too weak may not create a measurable interaction, whereas an excessively high dose can saturate cell death and conceal differences. Test earlier and later collection points, because checkpoint arrest and apoptosis do not necessarily peak together.

Ambiguous G-quadruplex or replication-stress results

Use at least two independent readouts, such as G-quadruplex imaging plus DNA-fiber analysis or micronucleus scoring. Confirm that the imaging signal is not caused by altered cell number or nuclear morphology. In REV1-focused experiments, include a matched rescue or control condition where feasible and avoid interpreting increased ATM/ATR signaling as proof of a specific lesion without structural or replication evidence.

Future outlook

The immediate opportunity is to test whether ATM inhibition changes the phenotype created by REV1 loss, DHX36 uncoupling, or G-quadruplex stabilization under defined radiation conditions. The reference study provides the mechanistic rationale, while AZD1390 provides a concentration-controlled way to perturb ATM signaling. Future work should therefore prioritize paired genetic and pharmacological experiments, time-resolved damage measurements, and carefully separated radiation-only and inhibitor-only effects. Such studies can clarify whether ATM blockade is merely a sensitizing background or a selective vulnerability in cells that struggle to replicate G-quadruplex DNA.